The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals’ (ATNM) Big Bet To view an enhanced version of ...

Despite SBRT to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and ...

Screenings will be available at selected BIG and CARiNG Pharmacy outlets in the Klang Valley from 15 November 2025 to 11 ...

Scientists of Tomsk Polytechnic University together with their colleagues have developed a new radiopharmaceutical for effective diagnosis of prostate cancer, including at early stages. The first ...

Health researchers at ANSTO, in collaboration with diverse teams across the organisation, have successfully undertaken ...

New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the ...

AdvanCell Pty Ltd ("AdvanCell"), a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Philina Lee, PhD as Chief ...

Q3 2025 Earnings Call Transcript November 10, 2025 FibroGen, Inc. beats earnings expectations. Reported EPS is $-1.61, ...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...